Outcomes of active surveillance for men with intermediate-risk prostate cancer. Read more about Outcomes of active surveillance for men with intermediate-risk prostate cancer.
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. Read more about Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.
Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. Read more about Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use.
Bevacizumab and everolimus in renal cancer: a rational way forward. Read more about Bevacizumab and everolimus in renal cancer: a rational way forward.
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. Read more about Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. Read more about In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. Read more about Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. Read more about Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.
Do not count out external-beam radiation therapy for high-risk prostate cancer. Read more about Do not count out external-beam radiation therapy for high-risk prostate cancer.
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. Read more about Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
